Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates advancing... Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates advancing in development with ongoing clinical programs: AVTX-002, AVTX-007, and AVTX-006. 詳細を表示
Proceeds from the full exercise of warrants issued in the first quarter of 2024 private placement bring the total gross proceeds from the transaction to $185 millionCash runway expected into at...
WAYNE, Pa. and ROCKVILLE, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.56 | -6.29921259843 | 8.89 | 9.41 | 8.01 | 104010 | 8.87911717 | CS |
4 | -0.99 | -10.6223175966 | 9.32 | 12 | 8.01 | 154432 | 9.27465358 | CS |
12 | -1.34 | -13.8572905895 | 9.67 | 15.4914 | 8.01 | 84139 | 10.49587542 | CS |
26 | -4.31 | -34.0981012658 | 12.64 | 15.4914 | 6.84 | 47658 | 10.36571775 | CS |
52 | -0.47 | -5.34090909091 | 8.8 | 34.46 | 3.9501 | 202210 | 17.69451606 | CS |
156 | -382.87 | -97.8706543967 | 391.2 | 1711.2 | 3.9501 | 7942633 | 35.82984624 | CS |
260 | -680.47 | -98.7906504065 | 688.8 | 1711.2 | 3.9501 | 7168403 | 39.28522751 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約